Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies

CONCLUSION: Rasburicase at 7.5 mg dose is an important agent for controlling laboratory and clinical TLS at 24 hours and extending its effect to the first week.PMID:34565690 | DOI:10.1016/j.clml.2021.08.009

Source: Clinical Lymphoma and Myeloma - September 27, 2021 Category: Cancer & Oncology Authors: Samet Yaman Semih Ba şcı G ökhan Turan Bahar Uncu Ulu Tu ğçe Nur Yiğenoğlu Mehmet Sinan Dal Merih K ızıl Çakar Fevzi Altunta ş Source Type: research